Has Leslie Zuniga, MD received payments from drug or device companies?

Yes. Drug and device makers reported $981,262 in general payments to Leslie Zuniga, MD across 1,394 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leslie Zuniga, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leslie Zuniga, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leslie Zuniga, MD

Neurology · Phoenix, AZNPI 1275977191

Payments from drug & device makers

$981,262in general payments, 2019–2025

Across 1,394 payments — averaging $703.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$753K
Merz Pharmaceuticals, LLC$81K
Bristol Myers Squibb$63K
Ares Trading SA$37K
Roche Products Limited$23K
AbbVie$4K
plus $21K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	165	$752,985
Merz Pharmaceuticals, LLC	11	$81,061
Bristol Myers Squibb	31	$62,721
Ares Trading SA	7	$36,751
Roche Products Limited	72	$22,894
AbbVie(2 entities)	244	$3,761
Biogen	129	$3,031
TG Therapeutics, Inc.	20	$2,952
AstraZeneca(2 entities)	41	$1,392
Teva Pharmaceuticals USA, Inc.	82	$1,274
UCB, Inc.	59	$1,217
Genentech USA, Inc.	48	$1,099
EMD Serono, Inc.	35	$997
Neurocrine Biosciences, Inc.	49	$988
Sanofi	38	$841
Amgen(2 entities)	26	$745
Lilly USA, LLC	44	$698
Pfizer	35	$627
Eisai Inc.	14	$414
Banner Life Sciences, LLC	35	$397
Amneal Pharmaceuticals LLC	22	$391
Biohaven Pharmaceuticals, Inc.	16	$291
Ipsen Biopharmaceuticals, Inc	10	$291
Lundbeck LLC	13	$250
Biohaven Pharmaceutical Holding Company Ltd.	14	$240
Upsher-smith Laboratories LLC	10	$223
Argenx US, Inc.	8	$217
Acadia Pharmaceuticals Inc	11	$210
Medicure Pharma Inc.	1	$167
Grifols USA, LLC	7	$145
Impel Pharmaceuticals Inc.	6	$143
Otsuka America Pharmaceutical, Inc.	5	$140
ANI Pharmaceuticals, Inc.	6	$134
Janssen Scientific Affairs, LLC	1	$134
Neurelis, Inc.	8	$131
Acorda Therapeutics, Inc	7	$120
Abbott	4	$109
Mallinckrodt Hospital Products Inc.	3	$86
Tanabe Pharma America, Inc.	4	$86
SK Life Science, Inc.	4	$79
GRT US Holding, Inc.	3	$69
Medtronic	3	$60
Vanda Pharmaceuticals Inc.	2	$55
Alnylam Pharmaceuticals Inc.	3	$50
Supernus Pharmaceuticals, Inc.	3	$50
E.r. Squibb & Sons, L.L.C.	3	$46
Corium, LLC	3	$43
Sanofi-aventis U.S. LLC	2	$41
Mallinckrodt Enterprises LLC	2	$40
Cycle Pharmaceuticals Inc	2	$39
Livanova USA, Inc.	2	$34
Jazz Pharmaceuticals Inc.	2	$31
Sumitomo Pharma America, Inc.	2	$30
Assertio Therapeutics, Inc.	2	$28
Johnson & Johnson	3	$23
Kyowa Kirin, Inc.	1	$21
Aprecia Pharmaceuticals, LLC	1	$21
Globus Medical	1	$20
Scilex Pharmaceuticals Inc.	1	$17
Catalyst Pharmaceuticals, Inc.	1	$16

How this compares

$981,262 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona →

Medicare billing

Part B allowed, 2024

$153,863

Medicare patients

227

Services billed

11,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Phoenix

David WeidmanPhoenix$7.4M
Stephen FlitmanPhoenix$4.4M
Barry HendinPhoenix$4.4M
Jeremy ShefnerPhoenix$3M
Danielle CabralPhoenix$2.8M
Suraj MuleyPhoenix$2.8M
Todd SchwedtPhoenix$2.8M
Todd LevinePhoenix$2.7M
Anna BurkePhoenix$2.2M
Maria OspinaPhoenix$2.1M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →